Cytokinetics Receives Health Canada Approval for MYQORZO Heart Treatment

Key Facts

1Cytokinetics announced that Health Canada issued a Notice of Compliance authorizing MYQORZO for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.

Cytokinetics announced that Health Canada issued a Notice of Compliance authorizing MYQORZO for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. The company stated via GlobeNewswire that the approval allows for the use of the once-daily oral treatment in patients experiencing cardiac contractility challenges.

The regulatory decision follows clinical data demonstrating the drug's effectiveness in reducing left ventricular outflow tract obstruction and improving exercise capacity. CYTK closed at $61.95 on October 16, 2026, with the stock trading between a low of $61.69 and a high of $63.9 during that session.